

Supplementary reference

S1. Anand S, Montez Rath ME, Han J et al. Antibody response to COVID-19 vaccination in patients receiving dialysis. JASN. 2021; 32: 2435-2438.

Supplementary Table 1: Responders versus Non-responders among vaccinated.

Total N = 116	Responders (n = 88, 75.8%)	Non-responders (n = 28, 24.1%)	P Value
Age (years)*	57.74 ± 13.4	58.57 ± 14.8	0.79
Males (%)	55(62.5)	16 (57.1)	0.57
Comorbidities			
Diabetes Mellitus (%)	36 (40.9)	15 (53.5)	0.28
Hypertension (%)	83 (94.3)	26 (92.8)	0.56
Coronary artery disease (%)	18 (20.4)	6 (21.4)	0.54
Malignancy (%)	-	2 (7.1)	0.01
Immunosuppression (%)	5 (5.6)	4 (14.2)	0.14
Tuberculosis (%)	7 (7.9)	1 (3.5)	0.45
Graft failure (%)	5 (5.6)	2 (7.1)	0.54
Haemoglobin (g/dl)*	10.10 ± 1.3	9.63 ± 1.6	0.18
Albumin (g/dl)*	3.72 ± 0.5	3.57 ± 0.5	0.24
Dialysis vintage (In months)**	20(9 - 41)	14 (4.2 – 47.5)	0.43
ChAdOx1-nCov-19(%)	75 (85.2)	22 (78.5)	0.11
BBV152 (%)	13 (14.8)	6 (21.4)	
Time interval b/w 1st and 2nd dose (days)*	76.0 ± 40.26	53.79 ± 26.8	0.00
Prior COVID 19 infection (%)	10 (11.3)	-	-

*Mean ± Standard Deviation, ** Median (Inter-quartile range)

Supplementary Table 2: Profile of COVID-19 infected in vaccinated and unvaccinated patients.

COVID-19 infection (n = 25)	COVID-19 pre- vaccination (n = 12)	COVID-19 post- vaccination (n = 13)	P Value
Age in years*	50.5 ± 22.3	60.3 ± 8.5	0.2
Male (%)	8 (66.6)	6 (46.1)	0.3
Dialysis vintage in months**	11.5 (3.75 – 30.75)	41 (21 – 81.75)	0.03
Comorbidities			
Diabetes Mellitus (%)	4 (33.3)	5 (38.4)	0.5
Hypertension (%)	12 (100)	12 (92.3)	-
Coronary artery disease (%)	4 (33.3)	2 (15.3)	0.3
Symptoms			
Fever (%)	9 (75)	10 (76.9)	0.6
Cough (%)	7 (58.3)	9 (69.2)	0.7
Breathlessness (%)	5 (41.6)	6 (41.6)	0.5
Diarrhoea (%)	2 (16.6)	1 (7.6)	0.4
Anosmia (%)	-	2 (15.3)	-
Myalgia (%)	-	2 (15.3)	-
Hospitalisation (%)	3 (25)	5 (38.4)	0.3
Oxygen requirement (%)	9 (75)	4 (30.7)	0.05
Ventilationrequirement (%)	0	1 (7.6)	-
Haemoglobin (g/dl)*	10.7 ± 1.4	10 ± 1.2	0.2
C- Reactive protein (mg/L)**	8 (5.6 - 109)	49 (43 - 100)	0.3
D-Dimer (mcg/ml)*	1471.1 ± 1067.7	1769.6 ± 877.1	0.5
Treatment			
Remdesivir (%)	6 (50)	4 (30.7)	0.3
Steroids (%)	9 (75)	9 (69.2)	0.6
Anticoagulation (%)	11 (91.6)	10 (76.9)	0.2
Post-COVID sequelae			
Fatigue (%)	6 (46.1)	7 (53.8)	0.5
Dyspepsia (%)	3 (25)	4 (30.7)	0.5
Myalgia (%)	3 (25)	4 (30.7)	0.4
Cough (%)	1 (8.3)	0	-
Headache (%)	1 (8.3)	1 (7.6)	0.7
Death (%)	1 (8.3)	1 (7.6)	0.7

*Mean ± Standard Deviation, ** Median (Inter-quartile range)